Cidara Therapeutics, Inc. (NASDAQ: CDTX) is identified as one of the Hot Growth Stocks to Invest in Now. Analyst Maxwell Skor from Morgan Stanley initiated coverage on CDTX with a Buy rating and a price target of $190, citing the potential of the company’s lead candidate, CD388, as a major player in the influenza prophylaxis market. The drug’s phase 3 interim results are expected in June 2026, with Skor noting its Fast Track and Breakthrough Therapy designation. The drug’s total addressable market is valued at over $5 million, offering a significant market opportunity for CDTX.

Read more at Yahoo Finance: Morgan Stanley Initiates Cidara Therapeutics (CDTX) With a Buy